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Dietary Mannan Oligosaccharides Modulate Gut
Microbiota, Increase Fecal Bile Acid Excretion, and Decrease
Plasma Cholesterol and Atherosclerosis Development
Lisa R. Hoving,* Saeed Katiraei, Marieke Heijink, Amanda Pronk, Lianne van der
Wee-Pals, Trea Streefland, Martin Giera, Ko Willems van Dijk, and Vanessa van Harmelen*
Scope: Mannan oligosaccharides (MOS) have proven effective at improving
growth performance, while also reducing hyperlipidemia and inflammation.
As atherosclerosis is accelerated both by hyperlipidemia and inflammation,
we aim to determine the effect of dietary MOS on atherosclerosis
development in hyperlipidemic ApoE*3-Leiden.CETP (E3L.CETP) mice, a
well-established model for human-like lipoprotein metabolism.
Methods and results: Female E3L.CETP mice were fed a high-cholesterol diet,
with or without 1% MOS for 14 weeks. MOS substantially decreased
atherosclerotic lesions up to 54%, as assessed in the valve area of the aortic
root. In blood, IL-1RA, monocyte subtypes, lipids, and bile acids (BAs) were
not affected by MOS. Gut microbiota composition was determined using 16S
rRNA gene sequencing and MOS increased the abundance of cecal
Bacteroides ovatus. MOS did not affect fecal excretion of cholesterol, but
increased fecal BAs as well as butyrate in cecum as determined by gas
chromatography mass spectrometry.
Conclusion: MOS decreased the onset of atherosclerosis development via
lowering of plasma cholesterol levels. These effects were accompanied by
increased cecal butyrate and fecal excretion of BAs, presumably mediated via
interactions of MOS with the gut microbiota.
1. Introduction
Atherosclerosis is a major cause of severe disease in modern
society and a leading cause of death.[1] Left untreated, atheroscle-
rosis leads to cardiovascular complications including heart attack
and stroke. The development of atherosclerosis is initiated by
LDL cholesterol deposition in the arterial wall, oxidation of these
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lipoproteins, and uptake by macrophages
leading to foam cell formation.[2] Ac-
cumulation of foam cells is associ-
ated with endothelial dysfunction,
influx of inflammatory cells, and
progression of atherosclerotic lesion
formation. This process is further ag-
gravated in the presence of systemic
inflammation. Atherosclerosis is thus
initiated by the formation of lesions
within the arterial wall,[3] and is driven
by both lipids and by inflammation.[4–6]
Although relatively efficient drugs are
available to inhibit the development of
atherosclerosis, additional strategies that
reduce inflammation and hyperlipidemia
are urgently required. One potential can-
didate includes dietary supplementation
with mannan oligosaccharides (MOS).
MOS can be derived from the outer
cell-wall membrane of bacteria, plants,
or yeast.[7] Yeast Saccharomyces cerevisiae-
derived MOS have been widely used
in livestock industry as an alternative
to antibiotics and as food supplemen-
tation to ameliorate performance by re-
ducing pathogenic contamination.[8–10]
Several studies demonstrated that MOS is able to inflam-
mation, both within the gastrointestinal tract[11] as well as
systemically.[12,13] Additionally, in different studies using a variety
of experimental animal models, it was shown that dietary sup-
plementation with MOS lowered plasma cholesterol levels.[14–16]
However, the mechanism by which MOS exert their effect is not
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fully established. A suggestedmode of action by whichMOSmay
improve inflammation is via interaction and modification of the
gut microbiota. According to Spring et al., MOS bind to type-
1 fimbriae of pathogenic bacteria and prevent their adherence
to the intestinal mucosa,[17] thereby reducing pathogen-induced
inflammation. Additionally, cholesterol levels might also be af-
fected by the interaction of MOS with the gut microbiota. Gut
microbiota play an important role in regulating bile acid (BA)
metabolism by converting primary BAs to secondary BAs.[18] Sec-
ondary BAs are relatively less efficiently reabsorbed and excreted
more via the feces compared to primary BAs.[18–20] Hepatic con-
version of cholesterol to BAs balances fecal excretion, which is
the major route for cholesterol catabolism and accounting for al-
most half of the cholesterol eliminated from the body per day.[21]
Therefore, differences in fecal BA excretion affects the enterohep-
atic circulation of cholesterol and may ultimately affect plasma
cholesterol levels.[22]
Given the potential anti-inflammatory and cholesterol-
lowering effects of MOS, we hypothesized that dietary MOS
supplementation will reduce atherosclerosis development via
interactions with the gut microbiota. In the present study,
we set out to determine the effect of dietary MOS sup-
plementation on systemic inflammation and plasma lipid
levels in the progression of atherosclerosis, using female
hyperlipidemic ApoE*3-Leiden.CETP (E3L.CETP) mice, a well-
established mouse model for hyperlipidemia and atherosclerosis
development.[23,24]
We found that MOS modulated the gut microbiota composi-
tion and activity, which was associated with increased fecal BA ex-
cretion. Increased BA excretion can explain lowered plasma total
cholesterol (TC) levels and subsequently decreased progression
of atherosclerosis.
2. Experimental Section
2.1. Mice and Diet
Female E3L.CETPmice of 11–15 weeks of age were fed a control
western-type diet (WTD) containing 0.1% cholesterol (Diet T; AB
Diets,Woerden, TheNetherlands) or this diet supplementedwith
1%MOS derived from S. cerevisiae (Actigen, Alltech, Ridderkerk,
The Netherlands) for a total period of 14 weeks. After a run-in
period of 3 weeks withWTD,mice were randomized according to
plasma total cholesterol, triglycerides (TG), body weight, and age.
Mice were housed under temperature- and humidity-controlled
specific pathogen-free (SPF) conditions with a 12:12 h light–dark
cycle and free access to food and water. During the diet inter-
vention, body weight and food intake were weekly measured.
After 14 weeks of intervention, non-fasted mice were sacrificed
using CO2 inhalation, perfused with ice-cold PBS through the
heart, and trunk blood was collected via heart puncture. Livers
were collected for further analysis. Mouse experiments were
performed in compliance with Dutch government guidelines
and the Directive 2010/63/EU of the European Parliament and
had received approval from the University Ethical Review Board
(Leiden University Medical Center, The Netherlands, permission
no. 13164).
2.2. Atherosclerosis Quantification and (Immuno)Histochemical
Analysis
After 14 weeks of dietary intervention, hearts were collected and
fixed in phosphate-buffered 4% formaldehyde, dehydrated in
70% ethanol, embedded in paraffin, and cross-sectioned (5 μm)
perpendicular to the axis of the aorta throughout the aortic root
area, starting from the appearance of open aortic valve leaflets.
Per mouse, four sections with 50 μm intervals were used for
atherosclerosis quantification. Obtained sections were stained
with hematoxylin phloxin saffron (HPS) for histological analy-
sis. Lesions were visually categorized for lesion severity accord-
ing to the guidelines of the American Heart Association adapted
for mice.[25] Various types of lesions were discerned: mild lesions
(types 1–3), severe lesions (types 4 and 5), and the absence of le-
sions defined as “non-diseased segments.” Rat monoclonal anti-
mouse antibody MAC3 (1:1000; BD Pharmingen, SanDiego, CA,
USA) was used to quantify macrophage area. Atherosclerotic le-
sion area and composition were analyzed using ImageJ software
(NIH, Bethesda, Maryland, USA).
2.3. Flow Cytometry
Circulatingmonocytes were analyzed using flow cytometry. After
lysis of red blood cells, pelleted cells were resuspended in FACS
buffer and stained for 30 min at 4 °C in the dark with fluores-
cently labeled antibodies listed in Table 1, Supporting Informa-
tion. Cells weremeasured on an LSR II flow cytometer usingDiva
6 software (BD Biosciences, CA, USA). Data were analyzed us-
ing FlowJo software (Treestar, OR, USA). Representative gating
schemes are shown in Figure S1, Supporting Information.
2.4. Plasma Parameters
At the indicated time points, 4 h-fasted (from 8:00 a.m. to 12:00
p.m.) blood samples were collected by tail vein bleeding into
chilled capillaries and isolated plasmawas assayed for TC and TG
using commercially available kits (Roche Diagnostics, Germany).
For determination of plasma HDL-cholesterol, apoB-containing
particles were precipitated from plasma with 20% polyethylene
glycol in 200 mM glycine buffer (pH 10) and TC was measured
in the supernatant. Non-HDL was calculated by subtracting HDL
values fromTC values. Cholesterol exposurewas calculated as the
cumulative exposure over the number of weeks theWTDwas fed.
The plasma cytokine IL-1RAwasmeasured using the R&DQuan-
tikine kit following the manufacturer’s standard protocol (R&D
Systems, Minneapolis, USA). Plasma concentrations of total BAs
were determined using a colorimetric assay kit (Diazyme Labo-
ratories, Poway, USA).
2.5. Liver Lipids
Lipids were extracted from the liver according to a protocol mod-
ified from Bligh and Dyer.[26] Liver samples were homogenized
in 10 μL ice-cold CH3OH/mg tissue. Lipids were extracted by
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the addition of 1800 μL CH3OH:CHCl3 (3:1 v/v) to 45 μL ho-
mogenate and subsequent centrifugation. The homogenate was
dried and dissolved in 2% Triton X-100, and TC content was as-
sayed as described above.
2.6. 16S rRNA Gene Sequencing and Profiling
For 16S rRNA sequencing, genomic DNA was isolated from ce-
cum samples and sent to the Broad Institute of MIT andHarvard
(Cambridge, USA). Microbial 16S rRNA gene was amplified tar-
geting the hyper-variable V4 region using forward primer 515F
(5’-GTGCCAGCMGCCGCGGTAA-3’) and the reverse primer
806R (5’-GGACTACHVGGGTWTCTAAT-3’). The cycling condi-
tions consisted of an initial denaturation of 94 °C for 3 min, fol-
lowed by 25 cycles of denaturation at 94 °C for 45 sec, anneal-
ing at 50 °C for 60 sec, extension at 72 °C for 5 min, and a final
extension at 72 °C for 10 min. Sequencing was performed us-
ing the Illumina MiSeq platform generating paired-end reads of
175 bp in length in each direction. Overlapping paired-end reads
were subsequently aligned. Details of this protocol are previously
described.[27]
Raw sequence data quality was assessed using FastQC,
version 0.11.2 (http://www.bioinformatics.babraham.ac.uk/
projects/fastqc/). Reads’ quality was verified using Sickle version
1.33 (https://github.com/najoshi/sickle) and low-quality reads
were removed. For visualizing the taxonomic composition of the
cecal microbiota and further β-diversity analysis, QIIME, version
1.9.1 was used.[28] In brief, closed reference OTU picking with
97% sequence similarity against GreenGenes 13.8 reference
database was performed. Jackknifed β-diversity of unweighted
UniFrac distances, with 10 jackknifed replicates was measured
at rarefaction depth of 5000 reads per sample.
2.7. Cecal Short-Chain Fatty Acid Analysis
Cecum short-chain fatty acid (SCFA) content was analyzed using
GC-MS as previously described with additional modifications.[29]
Briefly, aqueous extracts of cecal content were prepared and
added to acetone along with the internal standards acetate-d4,
propionate-d6, and butyrate-d8. Subsequently, SCFAs were
derivatized using pentafluorobenzyl bromide (PFBBr) (60 °C
for 30 min). Samples were extracted by the addition of n-hexane
and water. The n-hexane fraction was subjected for further
analysis. A Bruker Scion 436 GC coupled to a Bruker Scion TQ
MS (Bruker, Bremen, Germany) was employed. Injection was
performed using a CTC PAL autosampler (CTC Analytics, Zwin-
gen, Switzerland) splitless at 280 °C. The GC was equipped with
an Agilent VF-5ms (25 m × 0.25 mm i.d., 0.25 μm film thick-
ness) column (Agilent, Waldbronn, Germany). The following
temperature gradient was used: 1 min constant at 50 °C, linear
increase at 40 °C/min to 60 °C, kept constant for 3 min, linear
increase of 25 °C/min to 200 °C, linear increase at 40 °C/min to
315 °C, kept constant for 2 min. The transfer line and ionization
source temperature were 280 °C. Methane 99.995% was used as
chemical ionization gas and negatively charged molecular ions
were detected in the selected ion monitoring mode.
2.8. Fecal Cholesterol and Bile Acid Analysis
Feces was collected over a 24-h period for 3 consecutive days.
Fecal samples were dried at room temperature, weighed, and
homogenized. Fecal cholesterol, the fecal primary BAs cholic
acid (CA), α-muricholic acid (α-MCA), and β-muricholic acid
(β-MCA), and the secondary BAs hyocholic acid (HCA), de-
oxycholic acid (DCA), and ω-muricholic acid (ω-MCA) were
determined by capillary gas chromatography on an Agilent gas
chromatograph (HP 6890), equipped with a 25 m × 0.25 mm
CP-Sil-19-fused silica column (Varian, Middelburg, The Nether-
lands) and a flame ionization detector as described previously.[30]
2.9. RNA Isolation and qRT-PCR
RNA was extracted from snap-frozen liver samples using Nu-
cleoSpin RNA kit according to the manufacturer’s instructions
(Machery-Nagel, Germany). Concentrations and purity of RNA
were determined on a NanoDrop ND-1000 spectrophotometer
(Isogen, The Netherlands) and RNA was reverse-transcribed
using Moloney Murine Leukemia Virus Reverse Transcriptase
(Promega, The Netherlands). The mRNA expression level of
7-α-hydroxylase (Cyp7a1) and sterol 27-hydroxylase (Cyp27a1)
were determined by qRT-PCR, using SYBR green supermix
(Biorad, The Netherlands) and the gene-specific primers
for Cyp7a1 (forward: 5’-CAGGGAGATGCTCTGTGTTCA-
3’; reverse: 5’-AGGCATACATCCCTTCCGTGA-3’) and for
Cyp27a1 (forward 5’-TCTGGCTACCTGCACTTCCT-3’; re-
verse: 5’-CTGGATCTCTGGGCTCTTTG-3’). mRNA ex-
pression was normalized to the housekeeping gene 36b4
(forward: 5’-GGACCCGAGAAGACCTCCTT-3’; reverse: 5’-
GCACATCACTCAGAATTTCAATGG-3’), and expressed as fold
change versus control using the  CT method.
2.10. Statistical Analysis
Data are presented as means ± SEM. Normal distribution of the
data was tested using D’Agostino–Pearson omnibus normality
test, and data were comparedwith the unpaired Student’s t-test in
the case of normal distribution or with the nonparametricMann–
Whitney U test in the case of not normally distributed data. Cor-
relation analysis was performed using linear regression analysis.
The regression lines of the MOS-supplementedmice versus con-
trol mice were compared to identify whether the correlations dif-
fered between the groups. First it was tested whether slopes of
the lines differed and then whether intercepts of the lines dif-
fered. When the slopes and intercepts were not significantly dif-
ferent, linear regression analyses was performed on pooled data
of both groups. p < 0.05 was considered as statistically signifi-
cant. Analyses were performed using Graph Pad Prism version
7.0 (GraphPad Software, USA).
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Figure 1. MOS decreased atherosclerosis development. Mice were fed a WTD with or without MOS for 14 weeks. A) Representative cross sections
of the valve area of the aortic root stained with HPS are shown. Scale bar, 200 μm. B) Atherosclerotic lesion area was determined as a function of
distance (50 μm intervals) starting from the appearance of open aortic valve leaflets covering 150 μm. C) The mean atherosclerotic lesion area was
determined from the four consecutive cross sections, D) lesions were categorized according to lesion severity (type 1–5), E) the percentage of non-
diseased segments were scored, and F) macrophage area within the atherosclerotic lesions were quantified. Open bars/circles represent the control
group and closed bars/circles represent the MOS group. Values are presented as means ± SEM (n = 14–15 mice per group). *p < 0.05, **p < 0.01
versus control.
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3. Results
3.1. MOS Decreased Atherosclerosis Development
To assess whether MOS affects atherosclerosis, we determined
the progression of atherosclerosis in the aortic root after 14 weeks
of MOS supplementation. As illustrated by representative im-
ages in Figure 1A, MOS markedly reduced the atherosclerotic
lesion area throughout the whole aortic root (Figure 1B), which
resulted in a 54% reduction of the mean atherosclerotic lesion
area (p = 0.03; Figure 1C). Although the overall lesion severity
was generally profound in both intervention groups,MOS greatly
reduced type 5 lesions in the aortic root by 49% (p = 0.004; Fig-
ure 1D). Concomitantly, the number of non-diseased segments
was doubled after MOS supplementation (+147%; p = 0.01;
Figure 1E). However, MOS did not affect the macrophage con-
tent of the atherosclerotic lesions of these mice (Figure 1F). To-
gether, these findings demonstrated that MOS markedly delayed
the progression of atherosclerosis and attenuated the severity of
atherosclerotic lesions.
3.2. MOS did not Affect Markers of Systemic Inflammation
We subsequently assessed whether the attenuation of atheroscle-
rosis development and lesion severity after MOS supplementa-
tion was related to specific markers of systemic inflammation,
such as the percentages of circulatingmonocytes (Figure 2A) and
IL-1RA (Figure 2B).[31] Circulatingmonocytes andmonocyte sub-
sets (Ly6C+, Ly6Clow, and Ly6C−) were not affected by MOS (Fig-
ure 2A). Finally, MOS did not alter spleen and thymus weight
(Figure 2C). These results indicate that the MOS did not affect
specific markers of systemic inflammation after 14 weeks of di-
etary intervention.
3.3. MOS Inhibited the Gradual Increase in Plasma Total
Cholesterol Levels Without Affecting Plasma Triglycerides
As MOS is known to beneficially affect hyperlipidemia, we de-
termined the effect of MOS on plasma lipid levels. From week
4 onward, MOS significantly inhibited the gradual increase in
plasma TC levels compared to the control group (Figure 3A) with-
out affecting plasma TG levels (Figure 3B). In terms of choles-
terol exposure, this reduction in TC after MOS supplementation
was confined to a reduction in the non-HDL cholesterol fraction
(−21%; p= 0.008; Figure 3C). We performed regression analysis
on TC exposure versusmean atherosclerotic lesion area. Compar-
ison of the regression lines indicated that slopes (Fslopes = 0.34;
p = NS) and intercepts (Fintercepts = 0.77; p = NS) were similar
for MOS-supplemented mice and control mice (pooled data R2
= 0.6; p < 0.0001; Figure 3D). This implies that the reduction in
atherosclerotic lesion area after MOS supplementation was due
to the cholesterol-lowering effect of MOS.
Figure 2. MOS did not affectmarkers of systemic inflammation. A) Circulatingmonocytes, Ly6C+, Ly6Clow, and Ly6C− monocyte subsets as a percentage
of circulating leukocytes, B) plasma IL-1RA levels, and C) spleen and thymus weight were measured in mice fed a WTD with or without MOS for 14
weeks. Open bars/circles represent the control group and closed bars/circles represent the MOS group. Values are presented as means ± SEM (n =
14–15 mice per group). p < 0.05 was considered as statistically significant.
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Figure 3. MOS inhibited the gradual increase in plasma total cholesterol levels without affecting plasma triglycerides. Mice were fed a WTD with or
without MOS for 14 weeks. A) Plasma TC and B) TG were analyzed in 4-h fasted mice at the indicated time points. C) Cumulative TC, HDL, and non-
HDL cholesterol exposure were calculated and TC exposure was plotted against mean atherosclerotic lesion area. D) The dotted line represents the
regression line of the control mice and the straight line represents the regression line of the MOS-supplemented mice. Open bars/circles represent
the control group and closed bars/circles represent the MOS group. Values are presented as means ± SEM (n = 14–15 mice per group). *p < 0.05,
**p < 0.01 versus control.
3.4. The Cholesterol-Lowering Effect of MOS Was not Due to
Differences in Cholesterol Intake, Fecal Cholesterol Excretion, or
Liver Cholesterol Levels
Considering that plasma cholesterol levels might be affected by
alterations in dietary cholesterol intake or fecal excretion, we
assessed whether MOS affected these parameters. MOS did nei-
ther affect body weight (Figure 4A) nor food intake (Figure 4B),
indicating that both groups ingested similar amounts of food
and cholesterol via the diet. Furthermore, the fecal concentration
of cholesterol was not different after MOS supplementation
(Figure 4C), which demonstrates that fecal cholesterol excretion
was comparable between the groups. Additionally, liver weight
(Figure 4D) and liver TC (Figure 4E) were similar between
the groups. Together, these data illustrate that the plasma
cholesterol-lowering effect of MOS was not due to reduced
cholesterol intake, liver TC, or increased fecal cholesterol
excretion.
3.5. MOS Increased the Abundance of Cecal Bacteroides Ovatus
and Butyrate
MOS is thought to act in the gut via interactions with the gut
microbiota. To decipher the effects of MOS on gut microbiota,
we first determined the effect of MOS supplementation on gut
microbiota composition and the relative abundance of specific
microbial taxa by 16S rRNA gene sequencing. Clustering
analysis of 16S rRNA gene sequences by unweighted UniFrac
distances revealed no clustering based on intervention (Fig-
ure 5A), which indicated that the β-diversity did not change after
MOS supplementation. However, analysis of the gut microbiota
at various taxonomic levels demonstrated that MOS altered the
bacterial composition at phylum level, that is, MOS increased
the abundance of Bacteroidetes (fold-change = 1.5; p = 0.006;
Figure 5B; Table 1) and decreased the abundance of Firmicutes
(fold-change = −1.1; p = 0.03)(Figure 5B; Table 1). At lower
taxonomic levels, differences in microbial community between
the control mice and theMOS-supplementedmice becamemore
apparent, although significant effects were mainly found on
unidentified species (Table 1). One specific identified bacterium
in the phylum of Bacteroidetes which significantly increased with
95% after MOS supplementation, was B. ovatus (fold-change =
29.2; p = 0.0001; Figure 5C; Table 1). Therefore, t2he increase in
the abundance of the phylum Bacteroidetes was mainly explained
by an increase in B. ovatus. The decreased abundance of the
phylum Firmicutes was mostly explained by a decrease in the
order of Clostridiales (fold-change = −1.2; p = 0.04; Table 1),
the family Lachnospiraceae (fold-change = −1.4; p = 0.03;
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Figure 4. The cholesterol-lowering effect of MOS was not due to differences in cholesterol intake, fecal cholesterol excretion, or liver cholesterol levels.
A) Body weight, B) food intake, C) fecal cholesterol excretion, D) liver weight, and E) liver TC were determined in mice fed a WTD with or without MOS
for 14 weeks. Open bars/circles represent the control group and closed bars/circles represent the MOS group. Values are presented as means ± SEM
(n = 15 mice per group). p < 0.05 was considered as statistically significant.
Table 1), and unidentified taxonomic species in the genera of
Ruminococcus (fold-change = −2.3; p = 0.006; Table 1).
We further assessed bacterial function by analyzing SCFAs in
cecal content of these mice. MOS elevated cecal concentrations
of the SCFA butyrate (+31%; p = 0.01; Figure 5C). Collectively,
these data revealed that MOS altered the abundance of specific
microbial taxa and modulated microbial function by increasing
cecal butyrate.
3.6. MOS Increased Fecal Bile Acid Excretion
Plasma cholesterol levels might be affected via changes in fecal
BA excretion. Therefore, we determined whether MOS supple-
mentation led to differences in fecal BA excretion. The concen-
tration of the fecal primary BAs CA, α-MCA, and β-MCA were
considerably increased after MOS supplementation (Figure 6A).
For the secondary BAs,MOS increased the fecal excretion of DCA
(Figure 6B). Despite increasing fecal BA excretion, MOS did not
affect plasma BA concentrations (Figure 6C). We next performed
mRNA analysis on Cyp7a1 and Cyp27a1, the rate limiting en-
zymes in the major pathways for de novo BA synthesis. MOS
did neither affect the expression of Cyp7a1 nor Cyp27a1 in the
liver of these mice. Overall, we found that MOS increased the
excretion of both primary and secondary BAs in feces without
changing plasma BA levels and without affecting expression of
Cyp7a1 and Cyp27a1.
4. Discussion
Previous studies indicated that MOS decrease inflammation
and plasma lipid levels.[12–16] Here, we tested the hypothesis that
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Figure 5. MOS increased the abundance of cecal Bacteroides ovatus and butyrate. A) Principal coordinates analysis plot of unweighted UniFrac distances
of 16S rRNA gene sequences in which each circle represents an individual mouse. B) Microbiota composition at phylum level in cecal samples, C)
relative abundance of B. ovatus, and D) the cecal SCFAs acetate, propionate, and butyrate of mice fed a WTD with or without MOS for 14 weeks. Open
bars/circles represent the control group and closed bars/circles represent the MOS group. Values are presented as means ± SEM (n = 15 mice per
group). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 versus control.
MOS reduces atherosclerosis development via these pathways.
We found that S. cerevisiae-derived MOS indeed decreased
the progression and severity of atherosclerosis in E3L.CETP
mice. MOS reduced plasma cholesterol levels without affecting
specific markers of systemic inflammation. Therefore, the
decrease in atherosclerosis development after MOS supplemen-
tation can be explained by the cholesterol-lowering effect of
MOS.
MOS supplementation resulted in a reduction in plasma non-
HDL exposure by 21% and a decrease in total atherosclerotic le-
sion area in the aortic root by 54%. Similar reductions in plasma
cholesterol and atherosclerotic lesion area have been achieved in
E3L.CETPmice by statin treatment. For instance, low-dose ator-
vastatin treatment led to a reduction in plasma cholesterol levels
of 19% in E3L.CETPmice, accompanied by a reduction of50%
in the total atherosclerotic lesion area in the aortic root.[32] In an-
other study in E3L.CETP mice, rosuvastatin decreased plasma
cholesterol by 25% and the total atherosclerotic lesion area by
62%.[33] In this paper, rosuvastatin reduced atherosclerosis be-
yond and independent of the reduction achieved by cholesterol
lowering alone, which may be at least partly explained by its anti-
inflammatory activity.[34] Interestingly, the magnitude of the de-
crease in plasma cholesterol level and atherosclerotic lesion area
by statins and MOS are similar indicating that MOS may also
have pleiotropic effects beyond cholesterol lowering in the reduc-
tion of atherosclerosis.
We found that MOS specifically reduced the type 5 atheroscle-
rotic lesions. In humans, these lesions are characterized as ad-
vanced and vulnerable lesions, which are susceptible to plaque
rupture and to develop other cardiovascular complications such
as coronary heart disease or ischemic stroke.[35,36] In addition,
MOS-supplementedmice displayed 29%more non-diseased seg-
ments compared to the control group, indicating that MOS de-
creased de novo lesion formation in the aortic arch. Given the
strong effects of MOS on both plasma TC and atherosclerosis
development, comparable to the effects of statins in E3L.CETP
mice, dietaryMOSmight present a novel approach in the preven-
tion of atherosclerosis development and progression. It would be
interesting to investigate whether MOS exerts its lipid-lowering
effect when supplemented on top of statins.
MOS did not affect specific markers of systemic inflam-
mation associated with atherosclerosis,[31] despite having anti-
inflammatory properties in previous studies.[11–13] However, we
cannot exclude the possibility that MOS might have modulated
other systemic immune markers or that it has affected the im-
mune status more subtly or locally, for example within the
atherosclerotic plaque.
Spring et al. have proposed that MOS binds type-1 fimbriae
on pathogenic bacteria, preventing them from adhering to the
intestinal mucosa and inducing an inflammatory trigger.[17]
In the majority of previous studies, anti-inflammatory effects
of MOS were observed after the application of pathogenic or
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Table 1. Relative abundance of cecal microbiota.
Phylum Class Order Family Genus Species Control [%] MOS [%] Fold change p-valuea)
Bacteroidetes 17.98 26.31 1.5 0.006
Bacteroidia 17.98 26.31 1.5 0.006
Bacteroidales 2.96 5.72 1.9 0.02
Unidentified 1.63 5.50 3.4 0.0002
Unidentified 1.83 5.50 3.0 0.0002
Unidentified 1.83 5.50 3.0 0,0
Bacteroidaceae 6.77 10.83 1.6 0.04
Bacteroides 7.61 10.83 1.4 0.04
Unidentified 7.38 5.55 −1.3 0.15
ovatus 0.23 5.28 22.9 0.0001
Porphyromonadaceae 0.84 1.54 1.8 0.19
Parabacteroides 0.95 1.54 1.6 0.19
Unidentified 0.95 1.54 1.6 0.19
Rikenellaceae 2.26 5.18 2.3 0.01
Unidentified 2.54 5.18 2.0 0.01
Unidentified 2.54 5.18 2.0 0.01
S24-7 3.13 2.40 −1.3 0.16
Unidentified 3.52 2.40 −1.5 0.16
Unidentified 3.52 2.40 −1.5 0.16
Paraprevotellaceae 1.36 0.86 −1.6 0.62
Prevotella 1.53 0.86 −1.8 0.62
Unidentified 1.53 0.86 −1.8 0.62
Deferribacteres 4.44 5.64 1.3 0.39
Deferribacteres 4.44 5.64 1.3 0.39
Deferribacterales 4.44 5.64 1.3 0.39
Deferribacteraceae 3.94 5.64 1.4 0.39
Mucispirillum 4.44 5.64 1.3 0.39
schaedleri 4.44 5.64 1.3 0.39
Firmicutes 64.18 56.64 −1.1 0.03
Bacilli 0.76 0.38 −2.0 0.16
Lactobacillales 0.76 0.38 −2.0 0.16
Lactobacillaceae 0.67 0.38 −1.8 0.16
Lactobacillus 0.76 0.38 −2.0 0.16
Unidentified 0.76 0.38 −2.0 0.16
Clostridia 50.06 43.40 −1.2 0.04
Clostridiales 50.06 43.40 −1.2 0.04
Unidentified 31.05 31.46 1.0 0.12
Unidentified 34.93 31.46 −1.1 0.12
Unidentified 34.93 31.46 −1.1 0.12
Lachnospiraceae 4.55 3.16 −1.4 0.03
Dorea 1.23 0.67 −1.8 0.25
Unidentified 1.23 0.67 −1.8 0.25
Ruminococcus 3.89 2.49 −1.6 0.11
gnavus 3.89 2.49 −1.6 0.11
Peptostreptococcaceae 1.04 1.16 1.1 >.999
Unidentified 1.16 1.16 1.0 >.999
Unidentified 1.16 1.16 1.0 >.999
Ruminococcaceae 7.85 7.62 1.0 0.35
Oscillospira 7.20 6.92 1.0 0.81
(Continued)
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Table 1. Continued.
Phylum Class Order Family Genus Species Control [%] MOS [%] Fold change p-valuea)
Unidentified 7.20 6.92 1.0 0.81
Ruminococcus 1.64 0.70 −2.3 0.006
Unidentified 1.64 0.70 −2.3 0.006
Erysipelotrichi 13.36 12.86 1.0 0.90
Erysipelotrichales 13.36 12.86 1.0 0.90
Erysipelotrichaceae 11.88 12.86 1.1 0.90
Unidentified 0.71 1.46 2.1 0.23
Unidentified 0.71 1.46 2.1 0.23
Allobaculum 12.66 11.40 −1.1 0.74
Unidentified 12.66 11.40 −1.1 0.74
Proteobacteria 13.37 11.37 −1.2 0.47
Deltaproteobacteria 13.37 11.37 −1.2 0.47
Desulfovibrionales 13.37 11.37 −1.2 0.47
Desulfovibrionaceae 11.89 11.37 1.0 0.47
Bilophila 7.61 7.92 1.0 0.86
Unidentified 7.61 7.92 1.0 0.86
Desulfovibrio 5.76 3.45 −1.7 0.30
C21 c20 5.76 3.45 −1.7 0.30
Verrucomicrobia 0.03 0.04 1.4 0.54
Verrucomicrobiae 0.03 0.04 1.4 0.54
Verrucomicrobiales 0.03 0.04 1.4 0.54
Verrucomicrobiaceae 0.03 0.04 1.5 0.54
Akkermansia 0.03 0.04 1.4 0.54
muciniphila 0.03 0.04 1.4 0.54
p < 0.05 was considered statistically significant; MOS versus control; a)Significance according to Mann–Whitney U test
pro-inflammatory stimuli, such as E. Coli, Salmonella, or
LPS.[11–13] However, mice bred in our facility were kept un-
der SPF conditions and therefore were not challenged with
pathogenic stimuli. Whether a strong pathogenic stimulus is
required to detect anti-inflammatory effects of MOS, remains to
be further investigated.
Previous studies have shown that dietary MOS alters the gut
microbiota, although these studies were mainly conducted in
other species such as chickens,[37,38] juvenile rainbow trout,[39] or
turkeys.[40] In the present study conducted in mice, MOS also
interacted with the gut microbiota as shown by an increase in
butyrate levels in cecum as well as an increased abundance of
the phylum Bacteroidetes and a decrease in the phylum Firmi-
cutes. However, since the β-diversity did not change, this sug-
gests that MOS did not alter themicrobial composition on a large
scale. Notably, MOS induced the abundance of one specific iden-
tified species, B. ovatus. This bacterium is a well-known mannan
fermenter.[41–43] Therefore, we suggest that MOS served as a sub-
strate for B. ovatus to grow out. Interestingly, B. ovatus also ex-
presses bile salt hydrolases (BSH)[44,45] and accordingly is able to
deconjugate primary BAs into secondary BAs. Compared to pri-
mary BAs, secondary BAs are less efficiently reabsorbed in the
intestine and are relatively more excreted via the feces.[18–20] In-
deed, MOS increased the fecal output of secondary BAs, likely via
increasing the abundance of B. ovatus.
Regulation of plasma TC levels and BAmetabolism are tightly
linked as cholesterol from plasma serves as substrate for de novo
BA synthesis in the liver.[46,47] Increased fecal excretion of BAs
thus requires increased production of BAs. De novo synthesis of
BA in mice and humans predominantly involves the enzymes
Cyp7a1 and Cyp27a1. Since we did not observe differences in
the expression of Cyp7a1 and Cyp27a1, it seems likely that the
increased activity of both genes was due to post-transcriptional
regulation, alternative pathways involved in BA synthesis, or
that other pathways in the enterohepatic circulation of BAs were
affected.
In addition to increased secondary BA excretion, we also
observed an increase in primary BA excretion after MOS supple-
mentation. It is possible that MOS directly interacted with host
cells involved in enterohepatic signaling, indirectly affecting
recirculation of cholesterol or BAs, or that MOS acted as a BA
sequestrant leading to reduced reabsorption of BAs. However,
this seems unlikely since BA sequestrants usually result in
increased plasma TG levels,[48] which we did not observe in our
study.
In literature, there are indications that the SCFA butyrate is
associated with plasma cholesterol levels. In a previous study
performed in mice, cecal infusion of butyrate increased hep-
atic cholesterol synthesis, suggesting that butyrate might elevate
plasma cholesterol.[49] However, in another study performed in
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Figure 6. MOS increased fecal bile acid excretion. A) The fecal primary BAs cholic acid (CA), a-muricholic acid (a-MCA), β-muricholic acid (β-MCA), B)
the fecal secondary hyocholic acid (HCA), deoxycholic acid (DCA),ω-muricholic acid (ω-MCA), C) plasma total BAs, and D)mRNA expression analysis of
7-α-hydroxylase (Cyp7a1) and sterol 27-hydroxylase (Cyp27a1) were determined in mice fed a WTD with or without MOS for 14 weeks. Open bars/circles
represent the control group and closed bars/circles represent the MOS group. Values are presented as means ± SEM (n = 8–15 mice per group).
*p < 0.05 versus control.
rats, hepatic cholesterol synthesis was reduced after ingestion
of butyrate, albeit butyrate was given in combination with other
SCFAs.[50] It remains to be determined whether increased cecal
butyrate levels are involved in the cholesterol-lowering effect of
MOS.
In conclusion, MOS decreased the progression of atheroscle-
rosis up to 54% in E3L.CETP mice, which was largely explained
by a reduction in plasma non-HDL cholesterol. The cholesterol-
lowering effect of MOS was accompanied and likely explained by
modulation of the gut microbiota, increased cecal butyrate levels,
and increased fecal BA excretion.
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phy, Appl. Environ. Microbiol. 2015, 81, 3460.
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